论文部分内容阅读
目的:研究唑来膦酸和伊班膦酸钠治疗恶性肿瘤骨转移疼痛的药物经济学。方法:45例恶性肿瘤骨转移疼痛的患者随机分为两组,一组接受4mg唑来膦酸治疗,另一组接受4mg伊班膦酸钠治疗,比较两组患者首次住院双膦酸盐治疗的总费用、费用组成、疼痛缓解率、不良反应,进行药物经济学的费用-效果分析。结果:唑来膦酸组(n=23)总费用低于伊班膦酸钠组(n=22),分别为2 409.22元和3 903.64元(P<0.05);两组疼痛缓解有效率分别为78.3%和72.3%,无显著性差异(P>0.05);两组费用-效果比为31.75和53.99;不良反应发生率两组间无显著性差异(P>0.05)。结论:唑来膦酸是治疗恶性肿瘤骨转移的安全、有效、经济的药物。
OBJECTIVE: To study the pharmacology of zoledronic acid and ibandronate in the treatment of malignant bone metastases. Methods: Forty-five patients with bone metastases of malignant tumors were randomly divided into two groups. One group received 4 mg zoledronic acid and the other received 4 mg ibandronate. The first hospitalized bisphosphonate treatment was compared between the two groups The total cost, cost composition, pain relief rate, adverse reactions, cost-effectiveness analysis of pharmacoeconomics. Results: The total cost of zoledronic acid group (n = 23) was lower than that of ibandronate sodium group (n = 22), which was 2 409.22 yuan and 3 903.64 yuan respectively (P 0.05). The effective rates of pain relief (P> 0.05). The cost-benefit ratios of the two groups were 31.75 and 53.99. There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusion: Zoledronic acid is a safe, effective and economical drug for the treatment of malignant bone metastases.